Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 266

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 266
---
2023, 4,602,916 September 2023 Warrants were exercised into 409,667 common shares.   During the period between February 23, 2024 and March 22, 2024, 281,910 September 2023 Warrants were exercised into 81,469 common shares.   On June 28, 2024, 182,144 September 2023 Warrants were exercised into 54,877 common shares. |

On August 12, 2024, 80,526September 2023 Warrants were exercised into 23,197common shares.

| c. | On January 16, 2024, the Company issued 1,500,000 warrants with an exercise price of $1.60 per warrant in connection with its January 2024 Public Offering (“January 2024 Warrants”). Each warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“January 2024 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability at the time of the grant and are revalued at the end of each reporting period.   On February 23, 2024, 30,200 January 2024 Warrants were exercised into 30,200 common shares.   During the period between June 20, 2024 and July 16, 2024, 138,320 January 2024 Warrants were exercised into 138,320 common shares. |
| d. | During the year ended October 31, 2024, the Company recorded a gain on the revaluation of the total derivative warrant liabilities of $707,802 in the Consolidated Statements of Operations and Comprehensive Loss.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

F-22 CLEARMIND MEDICINE INC. Notes to the Consolidated Financial Statements (Expressed in United States Dollars)

| 7. | Derivative                      
 warrant liabilities (continued) |

| e. | The                                                                                                 
 binomial model was used to measure the derivative warrant liability with the following assumptions: |

|                         |     | October 31, 
 204         |                 |   |
|:------------------------|:----|:------------|----------------:|:--|
| Share Price             |     | $           |            1.39 |   |
| Exercise Price          |